Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The 2025 Nobel Prize in Physiology or Medicine honored a scientific breakthrough with hidden cardiovascular potential: regulatory T cells and peripheral immune tolerance. These mechanisms provide a paradigm shift for understanding and treating cardiovascular disease, dampening inflammation without compromising immunity, and offering safer and more effective therapies.
There is great interest in modeling human HFpEF in animals to identify underlying mechanisms and ultimately improve sorely needed therapies. Our current models are a step forward but still fall short in several crucial ways, particularly by not capturing the severity of heart failure features common in patients.
Heart failure and cancer share risk factors and biological pathways, yet their interplay remains underexplored. This Comment calls for coordinated research, precision medicine approaches and policy changes to advance the emerging field of cardio-oncology.
Low-dose colchicine is the only anti-inflammatory drug approved for secondary prevention of coronary disease. The CLEAR-SYNGERY trial of colchicine in acute myocardial infarction challenges the results of previous colchicine trials; however, clinicians should be aware of how its design and the COVID-19 pandemic affected the trial outcome.
The PET radiotracer 18F-flurpiridaz has undergone rigorous clinical testing and gained FDA approval for the evaluation of coronary artery disease. Its unique properties suggest 18F-flurpiridaz has the potential to transform the field of nuclear myocardial perfusion imaging and blood flow quantification, with far-reaching effects on cardiovascular care.
